GH Research (STU:1KA) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is GH Research Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. GH Research's annualized Gross Profit for the quarter that ended in Mar. 2025 was €0.00 Mil. GH Research's average Total Assets over the quarter that ended in Mar. 2025 was €238.11 Mil. Therefore, GH Research's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 0.00%.

GH Research Gross-Profit-to-Asset % Historical Data

The historical data trend for GH Research's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Gross-Profit-to-Asset % Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

GH Research Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of GH Research's Gross-Profit-to-Asset %

For the Biotechnology subindustry, GH Research's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GH Research's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GH Research's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where GH Research's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

GH Research Gross-Profit-to-Asset % Calculation

GH Research's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (207.517	+	179.801)	/ 2 )
	=	0	/	193.659
	=	0.00 %

GH Research's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	0	/	( (179.801	+	296.42)	/ 2 )
	=	0	/	238.1105
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

GH Research Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of GH Research's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (STU:1KA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

GHRS:USA

Address

Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95

Website

https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research Headlines

No Headlines